Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Oropharynx Cancer
NCT05800574Phase 2Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in oropharyngeal cancer (2 cohorts), sponsored by Fox Chase Cancer Center. Primary endpoint: Number of patients that develop cancer on the contra-lateral side of the neck at 12 months. Started Mar 2023; status: recruiting.
02
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT05800574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800574.